 Vancouver, British Columbia and Minneapolis, Minnesota--Newsfile Corp. - August 17, 2021 - Neovasc Inc. NASDAQ: NVCN TSX: NVCN Neovasc or the Company announced today that it has filed a supplement to the COSIRA-II Investigational Device Exemption IDE Study with the U.S. Food and Drug Administration FDA. Following multiple productive discussions with FDA over the past several months, the protocol for the previously approved COSIRA-II study has been supplemented in consideration of additional experience and key questions... 